Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davicioni, E.
Right arrow Articles by Anderson, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davicioni, E.
Right arrow Articles by Anderson, M. J.
[Cancer Research 66, 6936-6946, July 15, 2006]
© 2006 American Association for Cancer Research


Molecular Biology, Pathobiology, and Genetics

Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar Rhabdomyosarcomas

Elai Davicioni1,3, Friedrich Graf Finckenstein5, Violette Shahbazian5, Jonathan D. Buckley2,3,4, Timothy J. Triche1,3,5 and Michael J. Anderson1,3,5

Departments of 1 Pathology and 2 Preventive Medicine, 3 Keck School of Medicine, and 4 Norris Comprehensive Cancer Center, University of Southern California; 5 Department of Pathology and Laboratory Medicine, Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California

Requests for reprints: Michael J. Anderson, Department of Pathology and Laboratory Medicine, Saban Research Institute, Children's Hospital Los Angeles, 4650 Sunset Boulevard, MS 103, Los Angeles, CA 90027. Phone: 323-669-5624; Fax: 323-906-8081; E-mail: manderson{at}chla.usc.edu.

Alveolar rhabdomyosarcomas (ARMS) are aggressive soft-tissue sarcomas affecting children and young adults. Most ARMS tumors express the PAX3-FKHR or PAX7-FKHR (PAX-FKHR) fusion genes resulting from the t(2;13) or t(1;13) chromosomal translocations, respectively. However, up to 25% of ARMS tumors are fusion negative, making it unclear whether ARMS represent a single disease or multiple clinical and biological entities with a common phenotype. To test to what extent PAX-FKHR determine class and behavior of ARMS, we used oligonucleotide microarray expression profiling on 139 primary rhabdomyosarcoma tumors and an in vitro model. We found that ARMS tumors expressing either PAX-FKHR gene share a common expression profile distinct from fusion-negative ARMS and from the other rhabdomyosarcoma variants. We also observed that PAX-FKHR expression above a minimum level is necessary for the detection of this expression profile. Using an ectopic PAX3-FKHR and PAX7-FKHR expression model, we identified an expression signature regulated by PAX-FKHR that is specific to PAX-FKHR-positive ARMS tumors. Data mining for functional annotations of signature genes suggested a role for PAX-FKHR in regulating ARMS proliferation and differentiation. Cox regression modeling identified a subset of genes within the PAX-FKHR expression signature that segregated ARMS patients into three risk groups with 5-year overall survival estimates of 7%, 48%, and 93%. These prognostic classes were independent of conventional clinical risk factors. Our results show that PAX-FKHR dictate a specific expression signature that helps define the molecular phenotype of PAX-FKHR-positive ARMS tumors and, because it is linked with disease outcome in ARMS patients, determine tumor behavior. (Cancer Res 2006; 66(14): 6936-46)




This article has been cited by other articles:


Home page
Am Soc Clin Oncol Ed BookHome page
F. G. Barr and W. H. Meyer
Rhabdomyosarcoma: An Overview of Biology, Clinical Features, and the Current Children's Oncology Group Studies
ASCO Educational Book, January 1, 2008; 2008(1): 465 - 470.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
O. Slater and J. Shipley
Clinical relevance of molecular genetics to paediatric sarcomas
J. Clin. Pathol., November 1, 2007; 60(11): 1187 - 1194.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
F. G. Barr and R. B. Womer
Molecular Diagnosis of Ewing Family Tumors: Too Many Fusions... ?
J. Mol. Diagn., September 1, 2007; 9(4): 437 - 440.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
L.-W. Chang, B. R. Fontaine, G. D. Stormo, and R. Nagarajan
PAP: a comprehensive workbench for mammalian transcriptional regulatory sequence analysis
Nucleic Acids Res., July 13, 2007; 35(suppl_2): W238 - W244.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
H. C. Olguin, Z. Yang, S. J. Tapscott, and B. B. Olwin
Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination
J. Cell Biol., June 21, 2007; 177(5): 769 - 779.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2006 by the American Association for Cancer Research.